论文部分内容阅读
目的探讨氯雷他定联合布地奈德气雾剂治疗嗜酸粒细胞性支气管炎的临床疗效。方法 2010年1月~2013年12月来本院治疗的80例嗜酸粒细胞性支气管炎患者按随机数字表分成观察组45例,对照组35例;对照组仅给予布地奈德气雾剂2次,早晚各1次,400μg/次;观察组给予布地奈德气雾剂的基础上联合使用氯雷他定片10 mg,每晚睡前一次口服。两组均连续治疗4周,治疗后对咳嗽症状的评分、诱导痰嗜酸粒细胞百分比的比较和观察,并作统计学分析。结果治疗后3 d咳嗽症状的控制的比较两组差异具有统计学意义,但7 d后以及4周后两组差异无统计学意义。两组患者的诱导痰嗜酸粒细胞百分比比较差异无统计学意义。结论雷他定联合布地奈德气雾剂治疗嗜酸粒细胞性支气管炎能迅速改善患者症状,适合在临床上推广。
Objective To investigate the clinical efficacy of loratadine combined with budesonide aerosol in the treatment of eosinophilic bronchitis. Methods From January 2010 to December 2013, 80 patients with eosinophilic bronchitis treated in our hospital were randomly divided into observation group (n = 45) and control group (n = 35). The control group received only budesonide aerosol 2 times, morning and evening 1 times, 400μg / time; observation group was given budesonide aerosol based on the combined use of loratadine tablets 10 mg, taken orally at bedtime every night. Two groups were continuous treatment for 4 weeks, after treatment, the cough symptom score, induced sputum eosinophil percentage comparison and observation, and for statistical analysis. Results The control of cough symptom 3 days after treatment showed significant difference between the two groups, but there was no significant difference between the two groups after 7 days and 4 weeks. The two groups of patients induced sputum eosinophil percentage difference was not statistically significant. Conclusion Radiotherapy combined with budesonide aerosol treatment of eosinophilic bronchitis can quickly improve the symptoms of patients, suitable for clinical promotion.